Membranoproliferative glomerulonephritis and C3 glomerulopathy

Resolving the confusion

Sanjeev M Sethi, Carla M. Nester, Richard J H Smith

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Membranoproliferative glomerulonephritis (MPGN) denotes a general pattern of glomerular injury that is easily recognized by light microscopy. With additional studies, MPGN subgrouping is possible. For example, electron microscopy resolves differences in electron-dense deposition that are classically referred to as MPGN type I (MPGN I), MPGN II, and MPGN III, while immunofluorescence typically detects immunoglobulins in MPGN I and MPGN III but not in MPGN II. All three MPGN types stain positive for complement component 3 (C3). Subgrouping has led to unnecessary confusion, primarily because immunoglobulin-negative MPGN I and MPGN III are more common than once recognized. Together with MPGN II, which is now called dense deposit disease, immunoglobulin-negative, C3-positive glomerular diseases fall under the umbrella of C3 glomerulopathies (C3G). The evaluation of immunoglobulin-positive MPGN should focus on identifying the underlying trigger driving the chronic antigenemia or circulating immune complexes in order to begin disease-specific treatment. The evaluation of C3G, in contrast, should focus on the complement cascade, as dysregulation of the alternative pathway and terminal complement cascade underlies pathogenesis. Although there are no disease-specific treatments currently available for C3G, a better understanding of their pathogenesis would set the stage for the possible use of anti-complement drugs.

Original languageEnglish (US)
Pages (from-to)434-441
Number of pages8
JournalKidney International
Volume81
Issue number5
DOIs
StatePublished - Mar 1 2012

Fingerprint

Membranoproliferative Glomerulonephritis
Immunoglobulins
Alternative Complement Pathway
Complement C3
Antigen-Antibody Complex

Keywords

  • complement
  • glomerular disease
  • immunology
  • membranoproliferative glomerulonephritis (MPGN)
  • pathology

ASJC Scopus subject areas

  • Nephrology

Cite this

Membranoproliferative glomerulonephritis and C3 glomerulopathy : Resolving the confusion. / Sethi, Sanjeev M; Nester, Carla M.; Smith, Richard J H.

In: Kidney International, Vol. 81, No. 5, 01.03.2012, p. 434-441.

Research output: Contribution to journalArticle

Sethi, Sanjeev M ; Nester, Carla M. ; Smith, Richard J H. / Membranoproliferative glomerulonephritis and C3 glomerulopathy : Resolving the confusion. In: Kidney International. 2012 ; Vol. 81, No. 5. pp. 434-441.
@article{fa2f298a9ecb41c48f8cc179681bd120,
title = "Membranoproliferative glomerulonephritis and C3 glomerulopathy: Resolving the confusion",
abstract = "Membranoproliferative glomerulonephritis (MPGN) denotes a general pattern of glomerular injury that is easily recognized by light microscopy. With additional studies, MPGN subgrouping is possible. For example, electron microscopy resolves differences in electron-dense deposition that are classically referred to as MPGN type I (MPGN I), MPGN II, and MPGN III, while immunofluorescence typically detects immunoglobulins in MPGN I and MPGN III but not in MPGN II. All three MPGN types stain positive for complement component 3 (C3). Subgrouping has led to unnecessary confusion, primarily because immunoglobulin-negative MPGN I and MPGN III are more common than once recognized. Together with MPGN II, which is now called dense deposit disease, immunoglobulin-negative, C3-positive glomerular diseases fall under the umbrella of C3 glomerulopathies (C3G). The evaluation of immunoglobulin-positive MPGN should focus on identifying the underlying trigger driving the chronic antigenemia or circulating immune complexes in order to begin disease-specific treatment. The evaluation of C3G, in contrast, should focus on the complement cascade, as dysregulation of the alternative pathway and terminal complement cascade underlies pathogenesis. Although there are no disease-specific treatments currently available for C3G, a better understanding of their pathogenesis would set the stage for the possible use of anti-complement drugs.",
keywords = "complement, glomerular disease, immunology, membranoproliferative glomerulonephritis (MPGN), pathology",
author = "Sethi, {Sanjeev M} and Nester, {Carla M.} and Smith, {Richard J H}",
year = "2012",
month = "3",
day = "1",
doi = "10.1038/ki.2011.399",
language = "English (US)",
volume = "81",
pages = "434--441",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Membranoproliferative glomerulonephritis and C3 glomerulopathy

T2 - Resolving the confusion

AU - Sethi, Sanjeev M

AU - Nester, Carla M.

AU - Smith, Richard J H

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Membranoproliferative glomerulonephritis (MPGN) denotes a general pattern of glomerular injury that is easily recognized by light microscopy. With additional studies, MPGN subgrouping is possible. For example, electron microscopy resolves differences in electron-dense deposition that are classically referred to as MPGN type I (MPGN I), MPGN II, and MPGN III, while immunofluorescence typically detects immunoglobulins in MPGN I and MPGN III but not in MPGN II. All three MPGN types stain positive for complement component 3 (C3). Subgrouping has led to unnecessary confusion, primarily because immunoglobulin-negative MPGN I and MPGN III are more common than once recognized. Together with MPGN II, which is now called dense deposit disease, immunoglobulin-negative, C3-positive glomerular diseases fall under the umbrella of C3 glomerulopathies (C3G). The evaluation of immunoglobulin-positive MPGN should focus on identifying the underlying trigger driving the chronic antigenemia or circulating immune complexes in order to begin disease-specific treatment. The evaluation of C3G, in contrast, should focus on the complement cascade, as dysregulation of the alternative pathway and terminal complement cascade underlies pathogenesis. Although there are no disease-specific treatments currently available for C3G, a better understanding of their pathogenesis would set the stage for the possible use of anti-complement drugs.

AB - Membranoproliferative glomerulonephritis (MPGN) denotes a general pattern of glomerular injury that is easily recognized by light microscopy. With additional studies, MPGN subgrouping is possible. For example, electron microscopy resolves differences in electron-dense deposition that are classically referred to as MPGN type I (MPGN I), MPGN II, and MPGN III, while immunofluorescence typically detects immunoglobulins in MPGN I and MPGN III but not in MPGN II. All three MPGN types stain positive for complement component 3 (C3). Subgrouping has led to unnecessary confusion, primarily because immunoglobulin-negative MPGN I and MPGN III are more common than once recognized. Together with MPGN II, which is now called dense deposit disease, immunoglobulin-negative, C3-positive glomerular diseases fall under the umbrella of C3 glomerulopathies (C3G). The evaluation of immunoglobulin-positive MPGN should focus on identifying the underlying trigger driving the chronic antigenemia or circulating immune complexes in order to begin disease-specific treatment. The evaluation of C3G, in contrast, should focus on the complement cascade, as dysregulation of the alternative pathway and terminal complement cascade underlies pathogenesis. Although there are no disease-specific treatments currently available for C3G, a better understanding of their pathogenesis would set the stage for the possible use of anti-complement drugs.

KW - complement

KW - glomerular disease

KW - immunology

KW - membranoproliferative glomerulonephritis (MPGN)

KW - pathology

UR - http://www.scopus.com/inward/record.url?scp=84857113842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857113842&partnerID=8YFLogxK

U2 - 10.1038/ki.2011.399

DO - 10.1038/ki.2011.399

M3 - Article

VL - 81

SP - 434

EP - 441

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 5

ER -